SAR-444881 is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SAR-444881’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BND-22 is under development for the treatment of solid tumors including breast cancer, cervical cancer, colorectal cancer, adenocarcinoma or squamous cell carcinoma of the esophagus, gastric cancer, adenocarcinoma of gastroesophageal junction, head and neck squamous cell carcinoma, hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the skin and urothelial carcinoma. The drug candidate is a humanized IgG4 that acts by targeting Ig-like transcript 2 (ILT2) receptor. It is a monoclonal antibody. The drug candidate is being developed based on cell-internalizing antibody platform. It is administered through intravenous route.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of SAR-444881’s drug-specific PTSR and LoA scores, buy the report here.